[144] Arteris, Inc. SEC Filing

Rhea-AI Filing Summary

The Form 144 filing indicates that an unidentified insider of Arteris, Inc. (ticker AIP) intends to sell common shares under Rule 144.

• Shares to be sold: 31,202 common shares
• Estimated market value: $298,915.16
• Total shares outstanding: 41,977,728 (sale represents roughly 0.07% of the float)
• Approximate sale date: 06/27/2025
• Broker: Morgan Stanley Smith Barney LLC, New York
• Acquisition origin: Restricted Stock Units (RSUs) granted and vested on 10/05/2022

No other sales by this insider were reported during the past three months, and no additional remarks or 10b5-1 plan details were supplied. While the dollar amount is modest, the disclosure fulfils SEC requirements and signals a forthcoming insider disposition.

Positive

• None.

Negative

• Insider intends to sell 31,202 shares valued at approximately $298,915.16, which can be perceived as a modest negative sentiment signal, though the stake is immaterial (≈0.07% of shares outstanding).

Insights

Financial Analyst

TL;DR – Small insider sale (<0.1% float) appears immaterial; neutral signal for AIP investors.

The planned $0.3 million sale represents less than one-tenth of one percent of Arteris’s shares outstanding, suggesting minimal dilution or market-moving pressure. The shares stem from RSU grants—common for executive compensation—so monetisation is not unexpected. Absence of multiple sales or large blocks limits the read-through on management sentiment. With no earnings data or strategic updates attached, I view the filing as routine and not a catalyst for valuation changes.

Corporate Governance Expert

TL;DR – Standard Rule 144 notice; modest insider liquidity event, governance impact negligible.

Rule 144 requires advance notice for certain insider transactions. This filing discloses compliance and transparency, with no indication of undisclosed adverse information. The lack of a stated 10b5-1 plan date means the trade may be discretionary but still lawful. Volume is too small to raise red flags about insider confidence. Overall, corporate governance implications are neutral.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	31202	298915.16	41977728	06/27/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/05/2022	Restricted Stock Units	Issuer			31202	10/05/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Arteris (AIP) shares are being sold under the Form 144 filing?

The insider plans to sell 31,202 common shares.

What is the approximate dollar value of the planned AIP share sale?

The aggregate market value disclosed is $298,915.16.

When is the expected sale date for the AIP shares?

The filing lists an approximate sale date of 06/27/2025.

What percentage of Arteris's outstanding shares does the sale represent?

It represents about 0.07% of the 41,977,728 shares outstanding.

Where will the AIP shares be sold and through which broker?

The shares are to be sold on the NASDAQ through Morgan Stanley Smith Barney LLC.